Abstract: Short Communication The Effect of Ivermectin on Reducing Viral Symptoms in Patients with Mild COVID-19 K. U. ABBAS, S. MUHAMMAD1,2,3 AND S. F. DING* Department of Critical Care Medicine, 1Department of Radiology, Qilu Hospital of Shandong University, 2Center for Sectional and Imaging Anatomy Digital Human Institute, School of Basic Medical Sciences, Shandong University, 3Department of General Surgery, Qilu Hospital of Shandong University, Jinan, Shandong 250000, China Abbas et al.: Effect of Ivermectin in Patients with Mild COVID-19 Ivermectin is widely prescribed as a potential treatment for coronavirus disease 2019, despite uncertainty about its clinical benefit. To determine whether ivermectin is an efficacious treatment for mild coronavirus disease 2019 is the objective of the study. A total of 476 adult patients with mild symptoms for 7 d or fewer in Jinan, China, were enrolled and followed up. Patients were randomly selected to receive ivermectin, 300 μg/ kg body weight per day for 5 d or placebo. The median time to resolution of symptoms was 10 d (interquartile range, 9-13) in the ivermectin group whereas it was 12 d (interquartile range, 9-13) in the placebo group (hazard ratio for resolution of symptoms, 1.07 [95 % confidence interval, 0.87 to 1.32]; p=0.53 by log-rank test). By d 21, 82 % in the ivermectin group and 79 % in the placebo group had resolved symptoms. The most common solicited adverse event was headache, reported by 104 patients (52 %) who received ivermectin and 111 patients (56 %) who received placebo. The most serious adverse event was multiorgan failure. Among adults with mild coronavirus disease 2019, a 5 d course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild coronavirus disease 2019. Key words: Ivermectin, coronavirus disease 2019, pneumonia, severe acute respiratory syndrome coronavirus 2 Coronavirus Disease 2019 (COVID-19) has four clinical levels: Mild, moderate, severe and critical illness (Acute Respiratory Distress Syndrome (ARDS)) and more than half of people experience mild to moderate levels of disease[1]. Among COVID-19 patients referred to the hospital, 32 % were ARDS, 32 % require intensive care and 15 % of these patients die[2]. Findings reported from specialized hospitals approximately 20 % to 30 % of patients admitted with COVID-19 due to pneumonia need intensive care for respiratory support of which 4.42 % are supported by advanced organs with endotracheal intubation and ventilation. They needed mechanics[3,4]. According to World Health Organization epidemiological findings by the end of September 2021, about 5 million people in the world have been evacuated[5]. Despite consecutive mutations, especially in delta variant, there is a possibility that the effectiveness of anti-corona vaccine will be further reduced. Recent studies have shown that delta strain is more pathogenic and more contagious, which increases the need for more attention to treatment[6]. There are several treatments available for corona virus disease. These treatments include remdesivir 200 mg daily[7], hydroxychloroquine 400 mg for 5 d and azithromycin[8]. Studies also show that lithium carbonate has been effective in recovery of patients along with the use of antibiotics[9]. Because the treatments used on patients are not specific treatments, therapeutic approaches are needed to improve..